Search Abstracts

Background Despite the efficacy of ART, HIV-1 persistence in reservoirs, mostly formed by CD4 and macrophages hinders eradication. Nuclear import of pre-integration complex is assisted by proteins from mRNA processing pathways like CPSF6 (3´RNA-cleavage and polyadenylation factor 6) and  SRSF2/SC35 (Serine/Arginine-rich splicing factor 2). Dasatinib and ponatinib are tyrosine kinase inhibitors (TKIs) that interfere with HIV-1…

Background Long-term antiretroviral therapy (ART) in people with HIV (PWH) has been related to reduced levels of competent proviruses. We aimed to evaluate how time on ART affects reservoir size, reactivation capacity and cytotoxic response. Methods Cross-sectional study with 64 PWH who were on ART for <1 year (<1y)(n=11), 1 to 10 years (1-10y)(n=20), 10…

Background Viral reservoir is established early during primary HIV infection (PHI). Early antiretroviral therapy (ART) is essential to limit reservoir development. The aim of this work was to evaluate the impact of rapid bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) treatment on intact and defective proviral HIV-1 DNA in people with PHI. Methods Multicenter, single-arm clinical trial in confirmed…

Background The identification of host immune factors involved in the persistence of tissular HIV-1 reservoirs is crucial for the development of remission strategies. The intact HIV-1 reservoir is higher in the colon compared to other intestinal compartments at the chronic stage on ART, which may be related to the local loss of tissular resident memory…

Background HIV latency is a driver of persistence; however, cells expressing HIV RNA and proteins can still be detected after years of antiretroviral therapy (ART) and appear to drive ongoing stimulation of HIV-specific T-cells – indicating that some infected cells may be recognized by cytotoxic T lymphocytes (CTL) but are resistant to elimination. In this…

Background Analytic treatment interruption (ATI) studies utilizing broadly neutralizing antibody (bnAb) infusions are associated with delayed viral rebound if viruses found in the participants are sensitive to the bnAbs. Yet, viral sensitivity is typically evaluated only after the ATI has been conducted. For a future ATI that will enroll 35 participants from the RV254 Thai…

Background Individuals with nonsuppressible viremia (NSV) have persistent low-level viremia despite ART adherence and lack of drug resistance. A subset was reported to harbor deletions in the 5′ end of the HIV-1 genome, specifically within the 5′ PSI packaging element. We have previously reported three individuals with NSV and plasma variants harboring deletions in the…

Background The major barrier to HIV-1 cure is a small, stable pool of latently infected resting CD4+ T cells. Following cessation of antiretroviral therapy (ART), there is rapid, exponential viral rebound from this latent reservoir. Cure strategies aim to prevent viral rebound. Autologous neutralizing antibodies (aNAbs) have been shown to block outgrowth of a substantial…

Background Antiretroviral therapy (ART) is not a cure, and HIV rapidly rebounds upon ART interruption. Furthermore, people with HIV (PWH) on ART have elevated immune activation and inflammation which has been associated with increased risk of aging-associated diseases which may be driven by this viral persistence.  Methods To identify the potential mechanisms by which HIV…

Background We conducted a Phase 2, open-label study to evaluate the safety of N-803 with ART in acute HIV infection (AHI) and evaluated the impact on HIV viral load (VL), levels of vDNA and vRNA in CD4 T cells and lymph nodes (LN). Methods We randomized 12 participants in AHI to receive immediate ART (n=4, Fiebig 1-2)…